An integrative systems biology approach to understanding pulmonary diseases.

Chronic inflammatory pulmonary diseases such as COPD and asthma are highly prevalent and associated with a major health burden worldwide. Despite a wealth of biologic and clinical information on normal and pathologic airway structure and function, the primary causes and mechanisms of disease remain to a large extent unknown, preventing the development of more efficient diagnosis and treatment. We propose to overcome these limitations through an integrative systems biology research strategy designed to identify the functional and regulatory pathways that play central roles in respiratory pathophysiology, starting with severe asthma. This approach relies on global genome, transcriptome, proteome, and metabolome data sets collected in cross-sectional patient cohorts with high-throughput measurement platforms and integrated with biologic and clinical data to inform predictive multiscale models ranging from the molecular to the organ levels. Working hypotheses formulated on the mechanisms and pathways involved in various disease states are tested through perturbation experiments using model simulation combined with targeted and global technologies in cellular and animal models. The responses observed are compared with those predicted by the initial models, which are refined to account better for the results. Novel perturbation experiments are designed and tested both computationally and experimentally to arbitrate between competing hypotheses. The process is iterated until the derived knowledge allows a better classification and subphenotyping of severe asthma using complex biomarkers, which will facilitate the development of novel diagnostic and therapeutic interventions targeting multiple components of the molecular and cellular pathways involved. This can be tested and validated in prospective clinical trials.

[1]  R. A. Killington,et al.  Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation , 2008, Nature Medicine.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  I. Adcock,et al.  Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma , 2008, Thorax.

[4]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[5]  I. Adcock,et al.  Update on glucocorticoid action and resistance. , 2006, The Journal of allergy and clinical immunology.

[6]  W. Busse,et al.  Severe asthma in adults: what are the important questions? , 2007, The Journal of allergy and clinical immunology.

[7]  D. Postma,et al.  Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. , 1999, The European respiratory journal.

[8]  I. Pavord,et al.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids , 2002, Thorax.

[9]  Jason A. Papin,et al.  Comparison of network-based pathway analysis methods. , 2004, Trends in biotechnology.

[10]  Peter Hunter,et al.  A strategy for integrative computational physiology. , 2005, Physiology.

[11]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[12]  R. Stoughton Applications of DNA microarrays in biology. , 2005, Annual review of biochemistry.

[13]  D. Postma,et al.  Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. , 2005, The Journal of allergy and clinical immunology.

[14]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[15]  Charles Auffray,et al.  'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments. , 2005, Drug discovery today.

[16]  A. Brazma,et al.  Standards for systems biology , 2006, Nature Reviews Genetics.

[17]  I. Pavord,et al.  A new perspective on concepts of asthma severity and control , 2008, European Respiratory Journal.

[18]  L. Hood,et al.  Systems medicine: the future of medical genomics and healthcare , 2009, Genome Medicine.

[19]  Rolf Apweiler,et al.  Linking publication, gene and protein data , 2006, Nature Cell Biology.

[20]  E. D. de KLERK,et al.  Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. , 2001, American journal of respiratory and critical care medicine.

[21]  Michael E Phelps,et al.  Systems Biology and New Technologies Enable Predictive and Preventative Medicine , 2004, Science.

[22]  Xianlin Han An update on lipidomics: progress and application in biomarker and drug development. , 2007, Current opinion in molecular therapeutics.

[23]  K. Rabe,et al.  Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma , 2008, European Respiratory Journal.

[24]  D. Corry,et al.  Discovery of novel markers in allergic lung inflammation through proteomic-based technologies , 2008, Expert review of proteomics.

[25]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[26]  P. Barnes New therapies for asthma. , 2006, Trends in molecular medicine.

[27]  Bernhard O Palsson,et al.  Hierarchical thinking in network biology: the unbiased modularization of biochemical networks. , 2004, Trends in biochemical sciences.

[28]  S. Wenzel Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[29]  R. Aebersold,et al.  Advances in proteomic workflows for systems biology. , 2007, Current opinion in biotechnology.

[30]  David J. Reiss,et al.  Integrated biclustering of heterogeneous genome-wide datasets for the inference of global regulatory networks , 2006, BMC Bioinformatics.

[31]  Thomas D. Schmittgen,et al.  Integrating the MicroRNome into the study of lung disease. , 2009, American journal of respiratory and critical care medicine.

[32]  P. Sly,et al.  Animal models of asthma , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  A. Zwinderman,et al.  Risk factors of frequent exacerbations in difficult-to-treat asthma , 2005, European Respiratory Journal.

[34]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[35]  T. Hudson,et al.  Functional classes of bronchial mucosa genes that are differentially expressed in asthma , 2004, BMC Genomics.

[36]  N. Hanania Targeting airway inflammation in asthma: current and future therapies. , 2008, Chest.

[37]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[38]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[39]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[40]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[41]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[42]  A. Fernie,et al.  Metabolite profiling: from diagnostics to systems biology , 2004, Nature Reviews Molecular Cell Biology.

[43]  Mario Castro,et al.  Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. , 2008, The Journal of allergy and clinical immunology.

[44]  Richard Simon,et al.  Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Peter J Sterk,et al.  An electronic nose in the discrimination of patients with asthma and controls. , 2007, The Journal of allergy and clinical immunology.

[46]  Charles Auffray,et al.  From functional genomics to systems biology: concepts and practices. , 2003, Comptes rendus biologies.

[47]  D. Vercelli,et al.  Discovering susceptibility genes for asthma and allergy , 2008, Nature Reviews Immunology.

[48]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[49]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[50]  J. Bousquet,et al.  Effect of 17q21 variants and smoking exposure in early-onset asthma. , 2008, The New England journal of medicine.

[51]  Leroy Hood,et al.  Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. , 2004, Journal of proteome research.